🔗 Share this article

Given that America undertakes historic revisions to its vaccination guidelines, an unexpected name has surfaced in a surprising turn: Dr. Tracy Beth Høeg, a US-based physician and epidemiologist who rose to prominence by questioning coronavirus shots throughout the global health crisis and has concentrated on potential deaths following COVID-19 vaccination in her recent tenure at the US Food and Drug Administration (FDA).

Planned Changes to Pediatric Vaccine Schedule

Health officials planned to unveil sweeping revisions to the pediatric immunization program in December, bringing the US with Denmark’s national calendar, according to reports – a substantial departure that would place the US out of step with many the world with no evidence for benefit. This reveal has been pushed back until the coming year.

Rather than Vinay Prasad, Høeg is scheduled to speak at the meeting. She was just designated acting director of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth appointee to run the division this year.

Consolidating Power at the Agency

The acting appointment might represent a tighter collaboration between the drug and vaccine divisions as Dr. Høeg and Dr. Prasad solidify control at the FDA – and it suggests a greater focus upon dismantling already-approved immunizations at the FDA.

The new acting director has repeatedly called for ending certain pediatric shot schedules in the US so as to align more like the Danish model, a country with universal health coverage and a citizenry roughly the population of Wisconsin’s.

In her initial public appearances, she has persisted in emphasizing on vaccines – traditionally the domain of Prasad, chief of the FDA’s Center for Biologics Evaluation and Research (CBER) – rather than medication approval.

Questions Over Qualifications

Dr. Høeg has little discernible experience in drug development, oversight or administrative roles, which has been standard for previous heads of the CBER. She has served at the FDA as a key advisor to the agency head and the vaccine center since spring.

“It seems she lacks to have any of the qualifications” for running the drug-regulation department, remarked Jonathan Howard. “She lacks experience running a scientific study. She has no expertise in managing a sizeable institution. She has no expertise in drug approvals.”

Former heads of CBER would “be deeply familiar with legal statutes and the research of drug development”, commented Janet Woodcock. “Objectively, she has not acquired the type of experience that previous people who headed the center have had.”

The drug center has an immense portfolio at the FDA, Woodcock emphasized.

“The public just focuses on the novel medication approvals, but the generic drug division approves a multitude of generic drugs. There’s a biosimilars division, OTC medication office and more, and every single one need to be managed,” Dr. Woodcock said. “The responsibility you don’t keep your eye on, that’s the thing that I always told people is going to bite you.”

There is also, a major leadership component to the role, which manages in excess of 5,000 employees. “It’s a enormous management job, if you perform it correctly,” the former official added.

Official Statement and Disputed Programs

When asked about inquiries about Høeg’s credentials and whether this selection indicates greater collaboration among regulatory chiefs on vaccines, a press secretary said that the “inquiries rely on inaccurate presumptions”.

“Her experience is consistent with the duties of her job,” the spokesperson said, pointing to the time Dr. Høeg spent counseling the FDA commissioner on “pharmaceutical safety and regulatory science, including predictive safety algorithms and vaccine surveillance”.

As acting director, Høeg takes over the commissioner’s controversial expedited review system, a disputed rapid therapy clearance system that apparently troubled her former heads. “By what process are these drugs being selected for this voucher program? Who is making the choices?” Howard asked. “There’s a lot of secrecy occurring at the agency right now.”

Overall, he stated, “the Food and Drug Administration seems to be moving towards less stringent oversight of pharmaceuticals, with the exception of immunizations.”

Public History on Immunizations

Regarding vaccines, Dr. Høeg has a clearer, if troubling, track record, some experts have noted. She released a research paper using unconfirmed public submissions to assess the incidence of heart inflammation following Covid immunization. She advised the state of Florida chief medical officer Dr. Joseph Ladapo, who allegedly have changed statistics to indicate Covid vaccines are riskier than they are.

Among her “wish list” for the incoming government encompassed revising rules for novel immunizations and discontinuing “optional” immunizations, she remarked after the election on a podcast. At the FDA, Dr. Høeg has allegedly floated the idea of barring adolescent males from obtaining Covid vaccinations.

“She’s an thorough ideologue who starts off with her beliefs and works backwards to accommodate the data in a extremely deceptive, fraudulent way,” Howard said.

Taking Control and a “Campaign of Retribution”

Høeg aligned with fellow skeptics, {like|